REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/16/2026
Back to search
Official data from USPTO
PARVULET
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PARVULET
ST13
US500000088667306Class
5, 10, 40, 42
Filing
88667306
Registration
6269377
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
02/17/2026
Trademark type
Word
Nice classes
5, 10, 40, 42
Filing date
10/24/2019
Registration date
02/16/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/16/2021
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Philadelphia, PA
Examiner
MCDORMAN, ROGER THOMAS
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ADARE PHARMACEUTICALS, INC
ADARE PHARMACEUTICALS, INC
Representatives
Shawn Duckworth Dennemeyer & Associates, LLC
Technical classification
Nice Classes
Class 5Class 10Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations for the treatment of pain relief and pain managementfever managementshockhemorrhage and bleedingpre- and post-operative complications in the nature of hemorrhagebleedingthrombosisembolistrokeapoplexylesionsrespiratory and circulatory crises and dysfunctionscognitive dysfunctionsfibrosisinfectionsinflammationfever and sepsistraumas and emergenciesfracturesabrasionsburnspsychological and immunological shockpoisons and pollutionsanimal bites or stingsfeverrespiratory and cardiovascular shockcrises and dysfunctionshemorrhagebleedingthrombosisembolistrokeapoplexylesions and cognitive dysfunctionsphysical and psychological substance dependencedrug and alcohol dependencedrug tolerancewithdrawal symptomsconvulsionsAlzheimer diseasedementiasParkinson's diseaseinsufficient saliva and inability to swallowallergy/immunology disordersburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseases in the nature of fluAIDS/HIVanthraxplaguecholerabiological infectionsprion exposurediseases and afflictions of the gastroenterological systemdisbiosysdiseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesgenitourinary diseases and afflictionspremature laborpoison exposurecancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the earnose and throatdiseases and afflictions on the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictions; dietetic food adapted for medical use; diagnostic preparations for medical and veterinary use; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; synthetic peptides for pharmaceutical purposesfor the treatment of illnesses characterized by lack of such peptides and analogues thereof; vitamins; biologics being biopharmaceuticals and biologically active substances for the treatment of exocrine pancreatic insufficiencycystic fibrosis; pharmaceutical and nutraceuticals preparationsa drug delivery system comprising polymer-based oral tabletsoral powderoral liquidsoral suspensionsoral gelsoral emulsions for the immediate or controlledextendeddelayedpulsatilelocal release release of a wide variety of therapeutic agents within a certain time after ingestion; oral powder for reconstitutionnamely for immediate or controlledextendeddelayedpulsatilelocal release of a wide variety of therapeutic agents within a certain time after ingestion; medical gel; medicated candy; medicated chewing gum; medicated lollipops; sweets for medicinal purposessweets containing pharmaceutical and medical substances and compounds and nutraceuticals; drug delivery systems comprising polymer-based oral tabletsoral powder for immediate or controlledextendeddelayedpulsatilelocal release of a wide variety of therapeutic agents; drug delivery agents for various pharmaceuticalsdrugsmedicinescompounds and substances in the form of liquidsgelsgrainspowderemulsions; drug delivery powder for reconstitution in water before administration
Class 10
Surgicalmedicaldental and veterinary apparatus and instrumentsdrug delivery apparatus and instruments in the form of containers in the nature of blister packs and sachets for various pharmaceuticalsdrugsmedicinescompounds and substances sold without medication; spoonscups and syringes for administering pharmaceutical substances and medicines; drug delivery systemsdrug delivery patches sold without medicationimplantable drug delivery portsintravenous bags sold empty for intravenous therapy
Class 40
Treatment of materialsmillingmixinggrindingliquefyingpulverizingmelting and extrusion of medical and pharmaceutical substancescompounds and materials for others
Class 42
Scientific research; technology consultation in the field of scientific research; design for others in the fields of pain relief and pain managementfever managementinflammationpharmaceutical drug and medicine developmentdevelopment of medicines and medicine goods and packaging in the fields of traumas and emergenciesaddictionsagingallergy/immunologyburnsdiseases of the heart and blood vesselsdental and gum diseasesskin diseasesnutritional and dietary diseasesdiseases of the endocrinological system and pancreatic diseasesdiabetesepidemical diseasesdiseases and afflictions of the gastroenterological systemdisbiosys diseases of the bloodinfectious diseasesneurological diseasesnephrological diseasesdiseases in the obstetrical- and gynecological fieldoccupational diseases and afflictionscancerophthalmological diseasesdiseases and afflictions affecting the bonesjointscartilage material and musclesdiseases and afflictions of the ear-nose and throatdiseases and afflictions on the psychiatric fieldpulmonological diseases and afflictionsrheumatismurological diseases and afflictionsveterinary preparations for the treatment of bovinesheephorsespigspoultryostrichrodentsdogscatscamelsdonkeyselephants; chemicalbiochemicalbiological and bacteriological research and analysis; pharmaceutical drug and medicine development services; design for others in the field of drugs and medicines; development of pharmaceutical preparations and medicines; professional consultancy pertaining to pharmacologybiotechnical and biomedical and medical and pharmaceutical substancespreparations and compounds; professional consultancy in the field of researchdesign and development of medicine and the dispensing of pharmaceutical preparations; pharmaceutical drug development services comprised of scientificindustrialtechnologicalbio technicalpharmaceuticalbiomedical and clinical research in the field of drugs and drug candidates and biologics; medical and scientific researchconducting clinical trials of new drug candidates; consultation in the field of scientific research pertaining to chemicalpharmaceutical and medical goods; design for others in the field of medical packaging and equipment; development of pharmaceutical preparations and medicines with improved compliance and acceptability by the patients; consultation in the field of biotechnological and biomedical scientific research; biochemical and molecular biological analyses; in vitro and in vivo preclinical tests and clinical tests of drug candidates and potential drugs; consultancy and research regarding pharmaceuticals in gel-likegelling and viscous liquid dosage forms; consultancy and research pertaining to pharmacology in the nature of alternative drugs for the youngelderly and those with difficulties swallowing solid dosage forms such as pills and tablets; development of in vitro and in vivo preclinical tests of drug candidates and potential drugs and biologics; biochemical and molecular biological analyses of pharmaceuticals and nutraceuticals preparations to ensure efficacy and safety; scientificindustrialtechnological and biotechnological analysis in the field of pharmaceutical and veterinary drug and medicine analysisanalysis of drug delivery apparatus and containersanalysis of synthetic peptides or other biologics analogues for pharmaceutical purposesanalysis of peptide substratesanalysis for the purpose of detecting various toxinsanalysis of drug candidates and potential drugs; preparation of materials for promotional documents and campaigns
Publications
History of USPTO decisions and trademark events.
29 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/20/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/20/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/20/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/20/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/20/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/16/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/01/2020
PUBO
PUBLISHED FOR OPPOSITION
12/01/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/11/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
10/26/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
10/23/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/19/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/17/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/16/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/16/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/23/2020
GNRT
NON-FINAL ACTION E-MAILED
07/23/2020
CNRT
NON-FINAL ACTION WRITTEN
07/23/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/02/2020
ALIE
ASSIGNED TO LIE
07/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/22/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/03/2020
GNRT
NON-FINAL ACTION E-MAILED
02/03/2020
CNRT
NON-FINAL ACTION WRITTEN
02/03/2020
DOCK
ASSIGNED TO EXAMINER
01/30/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/30/2019
NWAP
NEW APPLICATION ENTERED
10/28/2019
Continuous trademark protection
Get notified about every new filing that threatens PARVULET or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.